Ceritinib is a targeted cancer therapy drug that belongs to a class of medications known as tyrosine kinase inhibitors (TKIs). It is specifically designed to treat patients with non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) rearrangements. Ceritinib works by inhibiting the activity of the ALK protein, which is involved in the growth and spread of cancer cells.
